Satsuma Pharmaceuticals, Inc. financial data

Industry
Pharmaceutical Preparations
Location
4819 Emperor Boulevard, Suite 340, Durham, NC
State of incorporation
DE
Fiscal year end
December 31

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 836 % -41.7%
Debt-to-equity 12.7 % +86.5%
Return On Equity -115 % -121%
Return On Assets -102 % -110%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 33.2M shares +5.09%
Common Stock, Shares, Outstanding 33.2M shares +5.09%
Entity Public Float 93.3M USD -41.3%
Common Stock, Value, Issued 3K USD 0%
Weighted Average Number of Shares Outstanding, Basic 33.2M shares +5.09%
Weighted Average Number of Shares Outstanding, Diluted 33.2M shares +5.09%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 40M USD -4.85%
General and Administrative Expense 14.4M USD +1.53%
Operating Income (Loss) -66.2M USD -17.6%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -64.8M USD -15.3%
Earnings Per Share, Basic -2.01 USD/shares +36.7%
Earnings Per Share, Diluted -2.01 USD/shares +36.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 19.5M USD -8.58%
Cash, Cash Equivalents, and Short-term Investments 41.4M USD
Assets, Current 43.4M USD -48.4%
Property, Plant and Equipment, Net 0 USD -100%
Operating Lease, Right-of-Use Asset 82K USD -66.4%
Other Assets, Noncurrent 22K USD -95.8%
Assets 43.5M USD -53.6%
Accounts Payable, Current 874K USD -51.4%
Accrued Liabilities, Current 4.84M USD +19%
Liabilities, Current 5.83M USD -11.5%
Operating Lease, Liability, Noncurrent 70K USD
Liabilities 5.83M USD -12.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax -5K USD +95.9%
Retained Earnings (Accumulated Deficit) -222M USD -41.2%
Stockholders' Equity Attributable to Parent 37.6M USD -56.7%
Liabilities and Equity 43.5M USD -53.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -11.4M USD +20.5%
Net Cash Provided by (Used in) Financing Activities -500K USD -101%
Net Cash Provided by (Used in) Investing Activities 14.5M USD -28.8%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 33.2M shares +5.09%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3.1M USD -43.9%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 19.5M USD -8.58%
Interest Paid, Excluding Capitalized Interest, Operating Activities 11K USD -74.4%
Deferred Tax Assets, Valuation Allowance 47.1M USD +45.6%
Deferred Tax Assets, Gross 47.1M USD +44.2%
Operating Lease, Liability 116K USD -51.7%
Depreciation 418K USD +3.21%
Payments to Acquire Property, Plant, and Equipment 24K USD -98.1%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -64.7M USD -14.8%
Lessee, Operating Lease, Liability, to be Paid 130K USD -47.4%
Operating Lease, Liability, Current 116K USD -14.7%
Lessee, Operating Lease, Liability, to be Paid, Year One 141K USD -29.9%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 14K USD +100%
Deferred Tax Assets, Operating Loss Carryforwards 30.7M USD +11.6%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 1.23M USD +202%
Operating Lease, Payments 100K USD 0%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 23K USD -93%
Share-based Payment Arrangement, Expense 5.56M USD +8.28%
Interest Expense 72K USD -71.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%